# A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

> **NCT02009449** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 353 (actual)

## Conditions studied

- Melanoma
- Prostate Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Pancreatic Carcinoma
- Non-small Cell Lung Carcinoma
- Solid Tumors
- Breast Cancer

## Interventions

- **DRUG:** Pegilodecakin
- **DRUG:** Paclitaxel or Docetaxel and Carboplatin or Cisplatin
- **DRUG:** FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- **DRUG:** gemcitabine/nab-paclitaxel
- **DRUG:** Capecitabine
- **DRUG:** Pazopanib
- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** nivolumab
- **DRUG:** Gemcitabine/carboplatin

## Key facts

- **NCT ID:** NCT02009449
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-15
- **Primary completion:** 2019-02-19
- **Final completion:** 2023-07-22
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2024-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02009449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02009449, "A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02009449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*